Plain-English translation of NCT06863571 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a specialized medication combination—made up of terazosin or urapidil combined with propranolol or esmolol—to see if it can reduce brain swelling in people who have had a large stroke. Brain swelling after a major stroke is a serious complication that can worsen outcomes, even after other stroke treatments succeed. Early lab studies suggest this medication combination may help the brain manage fluid and reduce swelling by working on how the brain handles water and waste clearance.
After a large stroke, dangerous swelling in the brain remains a major problem that doctors struggle to prevent, even with current treatments. This study aims to fill that gap by testing whether this medication approach can safely reduce swelling and improve how well people recover.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication combination for five days along with standard stroke care, or standard stroke care alone. Over those five days, you will receive either oral or intravenous medications (depending on which ones are chosen for you and your ability to take pills), with your blood pressure carefully monitored and adjusted. You will have follow-up brain imaging at 5–7 days after your stroke and again at 90 days to measure swelling and your overall recovery, along with regular safety check-ins throughout the study.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China